Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

MEVA Cognitive Wellness Platform Study for Adults (MEVA)

18 de mayo de 2026 actualizado por: Mentage LLC

Phase 1 Validation Study of the MEVA Cognitive Wellness Platform

The goal of this observational study is to evaluate the reliability, usability, and feasibility of the MEVA Cognitive Wellness Platform in community-dwelling adults aged 55 to 75.

The main questions it aims to answer are:

How consistent is the MEVA Global Cognitive Index when participants complete the MEVA activities again approximately 14 days later? How usable and acceptable is the MEVA platform for older adults in community settings? What completion rates, data quality patterns, and participant feedback are observed during use of the platform?

Participants will:

Complete a baseline study visit lasting approximately 45 to 60 minutes Complete a 7-activity digital cognitive wellness battery Answer questionnaires about usability, technology acceptance, and wellness experience Complete the Saint Louis University Mental Status (SLUMS) examination as an exploratory comparison measure If selected for the retest group, return approximately 14 days later to complete the MEVA activities again

MEVA is being evaluated as a cognitive wellness platform. It is not intended to diagnose, treat, prevent, screen for, or monitor any disease or medical condition.

Descripción general del estudio

Descripción detallada

This is a prospective, single-center, observational psychometric validation study of the MEVA Cognitive Wellness Platform in community-dwelling adults aged 55 to 75.

Platform Overview MEVA is a digital cognitive wellness platform developed by Mentage LLC to support cognitive engagement and healthy aging. MEVA uses real-world, Montessori-informed digital activities designed for older adult usability, autonomy, and engagement. The platform is not intended to diagnose, treat, prevent, screen for, or monitor any disease or medical condition, and is not used for clinical decision-making.

Study Purpose The primary objective is to evaluate test-retest reliability of the MEVA Global Cognitive Index over approximately 14 days. Secondary objectives include assessing usability, feasibility, task completion rates, internal consistency, participant experience, and exploratory convergent validity with an established cognitive measure.

Study Design All enrolled participants complete a baseline visit including informed consent, eligibility confirmation, demographic and health questionnaires, the PHQ-4 distress screening, the MEVA 7-activity digital cognitive wellness battery, the Saint Louis University Mental Status (SLUMS) examination, System Usability Scale, Technology Acceptance Model questionnaire, and brief qualitative feedback. The baseline visit lasts approximately 45 to 60 minutes.

The MEVA battery includes seven digital activities across four cognitive wellness domains: visuospatial ability, processing speed, language, and executive function. Performance across activities is combined into domain composite scores, which are then combined into the MEVA Global Cognitive Index, a composite wellness metric.

A randomly selected subset of participants (approximately 48 to 50) will complete a second visit approximately 14 days after baseline (allowed window: 11 to 17 days). At the retest visit, participants repeat the MEVA battery and complete a brief satisfaction questionnaire. The retest visit lasts approximately 30 to 35 minutes.

Recruitment and Health Equity Considerations Recruitment is community-based, including senior centers, libraries, faith-based organizations, wellness programs, and word of mouth. Recruitment is designed to support demographic and socioeconomic diversity. The study includes exploratory descriptive analyses examining MEVA performance, usability, and participant experience across age, education, technology experience, and self-reported health status to inform future culturally responsive wellness platform development.

Outcomes The primary outcome is test-retest reliability of the MEVA Global Cognitive Index, measured by intraclass correlation coefficient (ICC). Success is defined as ICC point estimate ≥ 0.75 with lower 95% confidence interval bound ≥ 0.60.

Secondary and exploratory outcomes include domain-level reliability, activity-level reliability, internal consistency (Cronbach's alpha, McDonald's omega), System Usability Scale score, Technology Acceptance Model scores, task completion rates, validity flag frequency, practice effects between visits, exploratory correlation with SLUMS total score, and exploratory age-stratified wellness score distributions.

Provisional Wellness Feedback Participants may receive provisional wellness feedback during or after MEVA completion. Any feedback is for research and wellness purposes only. It is not a medical assessment, diagnosis, screening result, treatment recommendation, or clinical interpretation.

Study Rationale This study provides foundational psychometric evidence to support MEVA's use as a wellness engagement tool in community and primary care settings. Findings will inform future validation studies in larger, more diverse populations and explore MEVA's potential role in health equity research and community-based cognitive wellness initiatives.

Tipo de estudio

De observación

Inscripción (Estimado)

100

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

Community-dwelling adults aged 55 to 75 years who are generally healthy or have stable chronic conditions and are interested in cognitive wellness research. Participants are recruited through community-based outreach, including senior centers, libraries, faith-based organizations, wellness programs, and word of mouth. Recruitment is designed to support demographic and socioeconomic diversity.

Descripción

Inclusion Criteria:

  • Adults aged 55 to 75 years
  • Community-dwelling (living independently in the community)
  • English fluency sufficient for informed consent, task instructions, and questionnaires
  • Able to provide informed consent using teach-back method
  • Able to use a computer or tablet for simple tap or drag interactions
  • Functional vision sufficient for on-screen tasks with usual corrective lenses
  • Functional hearing sufficient for spoken instructions with or without hearing aids
  • Interest in cognitive wellness and personal well-being
  • Available for baseline visit and possible retest visit approximately 14 days later
  • Transportation to study site or ability to participate remotely if permitted by protocol
  • Assistive devices and accommodations are permitted

Exclusion Criteria:

  • Severe visual impairment preventing completion of digital tasks
  • Severe motor impairment preventing interaction with tablet or web application
  • Known diagnosis of moderate or severe dementia, or inability to comprehend consent and task instructions
  • Current participation in another cognitive training or technology intervention study likely to confound outcomes
  • Recent hospitalization, emergency room visit, or acute exacerbation of a medical or psychiatric condition within the past 30 days that would impede study participation
  • Current substance use disorder likely to interfere with study adherence or completion
  • Recent intensive use of a similar structured cognitive wellness or brain training application

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
MEVA Study Cohort
Community-dwelling adults aged 55 to 75 who complete the MEVA digital cognitive wellness battery at baseline. A subset of participants will complete the MEVA battery again approximately 14 days later to assess test-retest reliability.
Participants complete an activity digital cognitive wellness battery designed to evaluate reliability, usability, feasibility, participant experience, and data quality. MEVA is being evaluated as a general wellness platform and is not used to diagnose, treat, prevent, screen for, or monitor any disease or medical condition.
Otros nombres:
  • MEVA Mentage Engagement and Vitality Assessment
  • Montessori Engagement and Vitality Assessment

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Test-retest reliability of the MEVA Global Cognitive Index
Periodo de tiempo: Baseline (Visit 1) and retest approximately 14 days later (Visit 2, allowed window 11-17 days)

Intraclass correlation coefficient (ICC) for the MEVA Global Cognitive Index between baseline and retest visits. The Global Cognitive Index is a composite wellness metric derived from performance across four cognitive wellness domains: visuospatial ability, processing speed, language, and executive function.

Reliability will be estimated using ICC(3,1), two-way mixed effects model, absolute agreement, single measurement. Success criterion: ICC point estimate

≥ 0.75 with lower 95% confidence interval bound ≥ 0.60.

Baseline (Visit 1) and retest approximately 14 days later (Visit 2, allowed window 11-17 days)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Task completion rate
Periodo de tiempo: Baseline and 14-day retest (11-17 day window)
Proportion of MEVA digital activities completed without technical errors or participant withdrawal from the activity.
Baseline and 14-day retest (11-17 day window)
Exploratory convergent validity with SLUMS
Periodo de tiempo: Baseline (Visit 1)
Pearson correlation between MEVA Global Cognitive Index at baseline and Saint Louis University Mental Status (SLUMS) examination total score.
Baseline (Visit 1)
Exploratory age-stratified score distributions
Periodo de tiempo: Baseline (Visit 1)
Descriptive statistics (mean, standard deviation, percentiles) for MEVA Global Cognitive Index and domain composite scores, stratified by age groups within the 55-75 year study population.
Baseline (Visit 1)
Test-Retest Reliability of Individual MEVA Digital Activity Scores
Periodo de tiempo: Baseline (Visit 1) and retest approximately 14 days later (Visit 2, allowed window 11-17 days)
Test-retest reliability of individual MEVA digital activity scores, measured by the intraclass correlation coefficient (ICC). ICC is a reliability statistic (not a correlation between different measures) ranging from 0 to 1, with higher values indicating greater consistency when the same measure is administered twice. ICC will be calculated using ICC(3,1), a two-way mixed effects model with absolute agreement for single measurements. Each MEVA digital activity generates a numerical performance score at baseline and retest; ICC quantifies the stability of these scores over approximately 14 days.
Baseline (Visit 1) and retest approximately 14 days later (Visit 2, allowed window 11-17 days)
Test-Retest Reliability of MEVA Domain Composite Scores
Periodo de tiempo: Baseline and 14-day retest (11-17 day window)
Test-retest reliability of MEVA domain composite scores, measured by intraclass correlation coefficient (ICC). ICC is a reliability statistic (not a correlation between different measures) ranging from 0 to 1, with higher values indicating greater consistency when the same measure is administered twice. ICC will be calculated using ICC(3,1), a two-way mixed effects model with absolute agreement for single measurements. MEVA generates domain composite scores for four cognitive wellness domains (visuospatial ability, processing speed, language, and executive function) at baseline and retest; ICC quantifies the stability of these domain scores over approximately 14 days.
Baseline and 14-day retest (11-17 day window)
Technology Acceptance Model Questionnaire Subscale Scores
Periodo de tiempo: Baseline (Visit 1)
Technology Acceptance Model (TAM) questionnaire scores for perceived usefulness and perceived ease of use of the MEVA platform. Items are rated on a 1 to 7 Likert scale. Subscale scores are calculated as mean item scores ranging from 1 to 7, with higher scores indicating greater perceived usefulness or ease of use.
Baseline (Visit 1)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Dwight Bellingham, MD, Bellingham Family Medicine

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de mayo de 2026

Finalización primaria (Estimado)

1 de agosto de 2026

Finalización del estudio (Estimado)

1 de diciembre de 2026

Fechas de registro del estudio

Enviado por primera vez

12 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de mayo de 2026

Publicado por primera vez (Actual)

19 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data will not be shared due to small sample size (target n=40 complete test-retest pairs), participant privacy considerations, and proprietary platform development. Aggregate results will be reported in scientific publications and regulatory summaries.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir